A phase II, open-label, randomized, two-arm study to investigate the efficacy and safety of two doses of the antibody-drug conjugate GSK2857916 in participants with multiple myeloma who have received three or more prior lines of treatment, are refractory to an inhibitor of multiple myeloma. proteasome and an immunomodulator and have not responded to an anti-CD38 antibody (DREAMM 2)
COMMERCIAL CLINICAL TRIAL
Clinical trial information
- Promoter: GLAXOSMITHKLINE, SA
- Phase: II
- Execution start: 24/07/2018
- End of execution: 30/06/2020
- IP: